A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A

Abstract excerpt

OBJECTIVE: To examine the potential impact of combining maternal age with fetal nuchal translucency thickness and maternal serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A) in screening for trisomy 21 at 10-14 weeks of gestation. METHODS: Maternal serum free beta-hCG and PAPP-A were measured by Kryptor, a random access immunoassay analyzer using...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gestational Trophoblastic Disease Studies
• Share to Parvovirus B19 Infection Studies
• Share to Prenatal Screening and Diagnostics